LYMPHOMAS

Latest News

Latest Videos

Episode 4: Dr. Fajgenbaums Commentary

Episode 3: Dr. Fajgenbaums Commentary

Episode 2: Dr. Fajgenbaums Commentary

Episode 1: Dr. Fajgenbaums Commentary

Dr. Peter Martin on Alternatives to Aggressive Therapy in Mantle Cell Lymphoma

Dr. John McCarty on Advice for Patients With Lymphoma Seeking Stem Cell Mobilization

Dr. Patrick Johnston on A Combination of Belinostat with Standard CHOP Chemotherapy in T-Cell Lymphoma

Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL

Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLL

CME Content

Multimedia

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Virginia Kaklamani, MD, DSc; William J Gradishar, MD, FASCO, FACP

Multimedia

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Video

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Aditya Bardia, MD, MPH; Heather McArthur, MD, MPH; Sonya Reid, MD, MPH

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Multimedia

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

Video

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Video

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

In-Person Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

In-Person Event

25th Annual International Congress on the Future of Breast Cancer® West

July 17-18, 2026

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

In-Person Event

24th Annual School of Breast Oncology

November 5-7, 2026

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Video

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

SOBO Slide Library

School of Breast Oncology® (SOBO) Slide & Lecture Library

Joyce O’Shaughnessy, MD

More News

Hodgkin Lymphoma Label for Brentuximab Vedotin Expanded by FDA

BySilas Inman

August 18th 2015

The antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) was recently approved by the FDA as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients who have Hodgkin lymphoma and are at risk of relapse or progression.

Anti-CD30 Therapies in Lymphoma Change Treatment Decisions

ByLorraine Myers

August 18th 2015

The development of novel targeted drugs, such as brentuximab vedotin (Adcentris), against discrete cell surface proteins, such as CD30, has awakened a new way of thinking about targeted cancer biology

Frits van Rhee, MD, PhD: Treatment Options

August 11th 2015

Frits van Rhee, MD, PhD: Patient's Diagnosis

August 11th 2015

Frits van Rhee, MD, PhD: Significant Tests in the Diagnostic Workup

August 11th 2015

Frits van Rhee, MD, PhD: Relevant Findings from Patient's Pathology Report

August 11th 2015

Frits van Rhee, MD, PhD: Initial Presentation

August 11th 2015

David Fajgenbaum, MD, MBA, MSc: Treatment Options

August 11th 2015

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnosis

August 11th 2015

David Fajgenbaum, MD, MBA, MSc: Significant Tests in the Diagnostic Workup

August 11th 2015

David Fajgenbaum, MD, MBA, MSc: Relevant Findings from Patient's Pathology Report

August 11th 2015

David Fajgenbaum, MD, MBA, MSc: Initial Presentation

August 11th 2015

Guess the Diagnosis: Case 2

August 11th 2015

Guess the Diagnosis

Frits van Rhee, MD, PhD: Potential Treatment Options

August 6th 2015

Frits van Rhee, MD, PhD: Most Likely Diagnosis

August 6th 2015

Frits van Rhee, MD, PhD: Patient's Diagnostic Workup

August 6th 2015

Frits van Rhee, MD, PhD: Pathology Report Findings

August 6th 2015

Frits van Rhee, MD, PhD: Patient's Initial Presentation

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Potential Treatment Options

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Most Likely Diagnosis

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnostic Workup

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Pathology Report Findings

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Patient's Initial Presentation

August 6th 2015

Guess the Diagnosis: Case 1

August 6th 2015

Guess the Diagnosis

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

ByVirginia Powers, PhD

July 8th 2015

Infusions of CTL019, a CAR-modified T-cell therapy against CD19, achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive DLBCL, MCL, and FL.

LYMPHOMAS

Latest News

Latest Videos

Episode 4: Dr. Fajgenbaum&#146;s Commentary

Episode 3: Dr. Fajgenbaum&#146;s Commentary

Episode 2: Dr. Fajgenbaum&#146;s Commentary

Episode 1: Dr. Fajgenbaum&#146;s Commentary

Dr. Peter Martin on Alternatives to Aggressive Therapy in Mantle Cell Lymphoma

Dr. John McCarty on Advice for Patients With Lymphoma Seeking Stem Cell Mobilization

Dr. Patrick Johnston on A Combination of Belinostat with Standard CHOP Chemotherapy in T-Cell Lymphoma

Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL

Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLL

CME Content

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

43rd Annual Miami Breast Cancer Conference®

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® West

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

24th Annual International Congress on the Future of Breast Cancer® East

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

24th Annual School of Breast Oncology

9th Annual School of Nursing Oncology™

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

School of Breast Oncology® (SOBO) Slide & Lecture Library

More News

Hodgkin Lymphoma Label for Brentuximab Vedotin Expanded by FDA

Anti-CD30 Therapies in Lymphoma Change Treatment Decisions

Frits van Rhee, MD, PhD: Treatment Options

Frits van Rhee, MD, PhD: Patient's Diagnosis

Frits van Rhee, MD, PhD: Significant Tests in the Diagnostic Workup

Frits van Rhee, MD, PhD: Relevant Findings from Patient's Pathology Report

Frits van Rhee, MD, PhD: Initial Presentation

David Fajgenbaum, MD, MBA, MSc: Treatment Options

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnosis

David Fajgenbaum, MD, MBA, MSc: Significant Tests in the Diagnostic Workup

David Fajgenbaum, MD, MBA, MSc: Relevant Findings from Patient's Pathology Report

David Fajgenbaum, MD, MBA, MSc: Initial Presentation

Guess the Diagnosis: Case 2

Frits van Rhee, MD, PhD: Potential Treatment Options

Frits van Rhee, MD, PhD: Most Likely Diagnosis

Frits van Rhee, MD, PhD: Patient's Diagnostic Workup

Frits van Rhee, MD, PhD: Pathology Report Findings

Frits van Rhee, MD, PhD: Patient's Initial Presentation

David Fajgenbaum, MD, MBA, MSc: Potential Treatment Options

David Fajgenbaum, MD, MBA, MSc: Most Likely Diagnosis

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnostic Workup

David Fajgenbaum, MD, MBA, MSc: Pathology Report Findings

David Fajgenbaum, MD, MBA, MSc: Patient's Initial Presentation

Guess the Diagnosis: Case 1

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications

Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC

Episode 4: Dr. Fajgenbaums Commentary

Episode 3: Dr. Fajgenbaums Commentary

Episode 2: Dr. Fajgenbaums Commentary

Episode 1: Dr. Fajgenbaums Commentary